Table 1.

RFLP classification and phenotypic, genotypic, and corrected drug resistance patterns for isolates from 61 patientsa

PatientRFLP patternFirst isolateInterval to last isolate (days)Last isolatePatient compliant
Phenotypic resistance patternMutation analysisCorrected patternAdditional resistance patternAdditional mutations
INHRIFSTREMB
1 Cluster 1H, R katG315 rpoB531 rrs-513 embB306 H, R, S, E 323 S, EYes
2 Cluster 1H, R, E katG315 rpoB531 rrs-513 embB306 H, R, S, E 176 S Yes
3 Cluster 1 H, R, S, E katG315 rpoB531 rrs-513 embB306 H, R, S, E 399No
4 Cluster 1 H, S katG315 rpoB531 rrs-513 embB306 H, R, S, E NAR, E Yes
5 Cluster 1 H, R, S, E katG315 rpoB531 rrs-513 embB306 H, R, S, ENA Yes
6 Cluster 1 H, R, S, E katG315 rpoB531 rrs-513b embB306 H, R, S, E 302 No
7 Cluster 1 H, R, S, E katG315 rpoB531 rrs-513 embB306 H, R, S, E175 No
8 Cluster 1 H, R, S, E katG315 rpoB531 rrs-513 embB306 H, R, S, E 77No
9 Cluster 1 H, R, S katG315 rpoB531 rrs-513 embB306 H, R, S, E 346 E Yes
10Cluster 1 H, R katG315 rpoB531 rrs-513 embB306 H, R, S, E NA S Yes
11Cluster 1 H, R, S, E katG315 rpoB531 rrs-513 embB306 H, R, S, E 277 Yes
12 Cluster 1H, R, S katG315 rpoB531 rrs-513 embB306 H, R, S, E NA E Yes
13 Cluster 1H, R, S, E katG315 rpoB531 rrs-513 embB306 H, R, S, E NA Yes
14 Cluster 1 H, R katG315 rpoB531 rrs-513 embB306 H, R, S, E 269 S, E No
15 Cluster 1 H, R, S, E katG315 rpoB531 rrs-513 embB306 H, R, S, ENA No
16 Cluster 2 H katG315d rpoB531b rpsL43b H, R, S 363 R, S Yes
17 Cluster 2H, R, S katG315d rpoB531 rpsL43b H, R, S NA Yes
18 Cluster 2H, R, S katG315d rpoB531 rpsL43 H, R, S 394No
19 Cluster 2 H, R, S katG315d rpoB531 rpsL43 H, R, S 215 Yes
20Unique H, S katG315d rpoB516b rpsL43 H, R, S 1,026 R No
21 Cluster 2H, R, S katG315d rpoB531 rpsL43 H, R, SNA Yes
22 Cluster 2H, R, S katG315d rpoB531 rpsL43 H, R, S660 E No
23 Cluster 2 H, S katG315db rpoB533b rpsL43 H, S201 No
24 Cluster 2 H, R, S katG315d rpoB531 rpsL43 H, R, SNA Yes
25 Cluster 2H, R, S katG315d rpoB531 rpsL43 H, R, SNA Yes
26 Cluster 2H, R katG315d rpoB531 rpsL43 H, R, S 444S No
27 Cluster 3 H, R katG315 rpoB531 H, R NA Yes
28Cluster 3 H, R katG315 rpoB531 H, R1,450 S Yes
29 Cluster 3 H, R katG315 rpoB531 H, R 14 Yes
30 Cluster 4 H c None 124 R rpoB526b No
31 Cluster 4 HH 493 Yes
32 Cluster 4H, R rpoB531 rpsL43 H, R, SNA No
33 Cluster 4 R rpoB531 R 1,188 H inhA15 No
34Cluster 5 H, R, S katG315 rpoB531 rpsL43 embB306b H, R, S, E NAYes
35 Cluster 5 H, R katG315 rpoB526 rpsL43 H, R, S NA SYes
36 Cluster 5 H, R, S katG315 rpoB526 rpsL43 H, R, S 103 No
37 Cluster 6H katG315 H NAYes
38 Cluster 6 H katG315 rrs-491 H, S 332 S Yes
39 Unique H c rpoB518b H 75Yes
40 Unique H HNA No
41 Unique None katG315d rpoB531 H, R 2,154 H, R, SNo
42 Unique None rpoB531b R NA R No
43Unique H katG315 HNA Yes
44 Unique H, R, E embB306 H, R, E 92 S rpoB526 No
45 Unique R inhA15b rpoB531 R NA Yes
46Unique H, S katG315 H, S 253 EYes
47 Unique H None 268 rpoB516 No
48 Unique H H613 R, S rpoB531 No
49 Unique HH NA No
50Unique H, R, E rpoB516b embB306 H, R, E 683 S inhA34 No
51 Unique HH NA Yes
52 Unique H, S katG315 c H, S 131 R rpoB526 Yes
53 UniqueH H NA Yes
54 Unique H rpoB531 H, R 307 R rrs-491 No
55 Unique H rrs-491 H 669 Yes
56 Unique H kasA269b H NANo
57 Unique H, R rrs-491 None NA NA
58Unique H H NAYes
59 Unique H katG315 rpoB526 rpsL43 embB306 H, R, S, E 1,056 S, E, R Yes
60 Unique H katG315 HNA Yes
61 Unique H, S katG315d+ rrs-513 H, SNA No
  • a H, INH; R, RIF; S, STR; E, EMB. Mutation analysis for first isolates indicates the genes encoding resistance to the indicated drugs. katG315, AGC→ACC (Ser→Thr); katG315d, AGC→ACA (Ser→Thr);katG315d+, katG315d plusinhA15 (C→T−15; putative promoter);kasA269, GGT→GAT (Gly→Ser); rpoB531, TCG→TTG (Ser→Leu); rpoB526, CAC→TAC (His→Tyr);rpoB516, GAC→GTC (Asp→Val); rpoB518d, AAC (Asn) deletion; rpoB533, CTC→CCC (Leu→Pro);embB306, ATG→GTG (Met→Val); rpsL43, AAG→AGG (Lys→Arg); rrs-491, C→T491;rrs-513, A→C513; inhA34, C→T−34 (putative promoter). NA, not available. Mutations were confirmed using mutant probes in conjunction with the dot blot method.

  • b The presence of the mutation was confirmed by DNA sequencing.

  • c —, The absence of a specific mutation was confirmed by DNA sequencing.